BioNexus Gene Lab shareholders approve reverse stock split at 1:5 to 1:10 ratio

BioNexus Gene Lab Corp

98.36% of votes cast (4.94B) approved reverse stock split; ratio range of 1:5 to 1:10 at Board discretion.
Series Z Preferred Stock with 5B votes mirrored common stock votes exclusively for this proposal.
Adjournment proposal also passed with 98.60% approval.
Special Meeting held March 19, 2025; no other matters voted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.